Zenocutuzumab

from OncoPharm · host John Bossaer

A first-in-class approval of a bispecific HER2-HER3 monoclonal antibody for NRG1 fusion (+) NSCLC and pancreatic cancer.

Episode metadata supplied by the publisher feed · Published Dec 5, 2024

Embed this episode

Attribution link and audio player

Ready to play

Zenocutuzumab

0:00 12:45

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

No similar episodes found.

No similar podcasts found.

This episode is 12 minutes long.

This episode was published on December 5, 2024.

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!